子宫内膜癌治疗药物的研究进展

药物治疗是子宫内膜癌治疗的重要组成部分，常用药物包括激素治疗药物（孕激素、抗雌激素药物、促性腺激素释放激素激动剂）、化疗药物（紫杉醇、铂类、蒽环类）和靶向药物（表皮生长因子受体拮抗剂、哺乳动物雷帕霉素靶蛋白抑制剂等）。随着研究的深入，越来越多的抗子宫内膜癌新靶点被发现，包括血管内皮生长因子（VEGF）、聚腺苷二磷酸核糖聚合酶（PARP）、程序性死亡受体1（PD-1）和PD-1配体（PD-L1），中药和天然单体化合物也是目前的研究热点。对子宫内膜癌治疗药物的作用机制及研究进展进行综述，以期对该病治疗及新药研发有所裨益。

Research progress in drug treatment of endometrial cancer

Drug therapy is an important part of endometrial cancer (EC) treatment. Commonly used clinical drugs include hormone therapy drugs (progestins, anti-estrogen drugs, gonadotropin releasing hormone agonists), chemotherapy drugs (paclitaxel, platinum Drugs, anthracyclines) and targeted drugs (epidermal growth factor receptor antagonists, mammalian target of rapamycin inhibitors, etc.). With the in-depth study of the mechanism, more and more new anti-EC targets have been discovered, including vascular endothelial growth factor (VEGF), polyadenosine diphosphate ribose polymerase (PARP), programmed death receptor 1 (PD-1) and PD-1 ligand (PD-L1). At the same time, the treatment of EC with traditional Chinese medicine and natural monomer compounds is also a hot spot of current research. The mechanism of action of EC drugs and the research progress are summarized, hoping to be beneficial to the treatment and new drug development of EC.